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ABSTRACT 
Salmonella enterica ser. Typhimurium type B flagellin monomer (FliC), when 
recombinantly expressed with an antigen, is an activator of cell types involved in innate and 
adaptive immunity by TLR5 stimulation. Large-scale production of recombinant full-length and 
fusion flagellin constructs has been achieved in E. coli. However, manufacturing outcomes vary 
with inserted antigen properties, and in vitro screening of fusion constructs is costly and time-
consuming. In this study, scalable process manufacturing and high-throughput in silico screening 
of recombinant flagellin-based products were characterized. Full-length FliC was expressed in E. 
coli in both flask and bioreactor scale, subsequently purified, and compared to research-grade 
commercial FliC standard. To aid rapid in silico screening of recombinant FliC fusion constructs, 
a modified Synthetic FliC platform housing multiple restriction enzyme sites in the non-
conserved hypervariable D3 and terminal region was used to incorporate Respiratory Syncytial 
Virus (RSV) protein fragments G (aa 130 – 230) and conformation-sensitive F (Palivizumab-
binding antigenic site II, aa 253 - 278). Fragments were inserted in multiple locations with varied 
 	
length linker piece attachments and screened in silico for physiochemical properties, epitope 
conformation, and epitope exposure. Out of 22 FliC-RSV fusion candidates screened, five were 
selected, cloned into an inducible expression vector, transformed in E. coli BL21, and 
overexpressed in flasks or bioreactor. Expressed fusion protein was purified by PEG 
precipitation, 2-phase separation, and column chromatography, and assessed for bioactivity by 
indirect ELISA, specific TLR5 assay, and endotoxin levels using the LAL chromogenic kinetic 
assay. All FliC-RSVF fusion proteins demonstrated TLR5-activity, specific antibody affinity, 
>95% purity, low manufacturing cost and time, and FDA acceptable endotoxin levels. These 
findings highlight the potential for a scalable, flexible, and cost-effective flagellin platform that 
is compatible with rational vaccine design, allowing rapid screening, production, and universal 
process standardization. 
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1 INTRODUCTION 		
Vaccination continues to be the most valuable defense strategy against infectious 
pathogens. Despite their success, there is still a need to update current vaccines and target 
pathogens we lack vaccination for such as Respiratory Syncytial Virus (RSV), tuberculosis, and 
malaria. Therapeutic vaccines are also being developed to target chronic conditions such as 
cancer. Vaccine research is challenging and expensive, the design process is lengthy, 
development ranges from 5 - 18 years [Plotkin et al., 2017], and the average cost to bring a 
pharmaceutical drug to market is $800 million [Congress of the US, 2006]. There is a great need 
to reduce time and costs associated with development and vaccine platforms are being 
characterized to establish proof-of-concept and screen candidates quickly. Recombinant subunit 
vaccines are less expensive and allow rapid production, but may lack the ability to evoke long-
term adaptive immunity.          
 
 Flagellin as a vaccine platform 1.1		
Toll-like Receptor 5 (TLR5), a subset of pattern recognition receptors (PRRs), recognize 
pathogen-associated molecular patterns (PAMPs), leading to activation of the innate immune 
system [Janeway, and Medzhitov, 2002]. TLRs binding to its specific PAMP ligand, enhances 
host immune responses to shape the acquired adaptive immune system [Medzhitov et al., 1997] 
by 1) initiating host intracellular pathway leading to production of inflammatory cytokines 
[Pasare, and Medzhitov, 2003], 2) upregulating expression of genes related to phagocytosis, and 
3) upregulation of major histocompatibility complex class II (MHC II) expression and 
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costimulatory molecules in antigen presenting cells (APCs) [Medzhitov et al., 1997; Yamamoto 
et al., 2002] (Fig. 1).  
 
	
Fig. 1. TLR PAMP recognition, signaling, and fragment presentation to T-cells [Gupta et al., 2014]. 
TLR receptors in host immune cells recognize and PAMPs and stimulate intracellular pathways to induce 
adaptive immunity.   
 
 
Bacterial flagella, structures responsible for aiding Gram-negative organism motility in 
an aqueous medium, also facilitate attachment to host cells and are recognized as a correlate of 
pathogenic infection by vertebrate host immune system [Mobley et al., 1996]. Conserved regions 
of flagellin subunit monomer FliC, which are required for flagella function and bacterial 
motility, are recognized by TLR5 and intracellular nucleotide-binding oligomerization domain-
like Receptor Card 4 (NLRC4) [Franchi et al., 2006] (Fig. 2). TLR5 recognizes the constrained 
D1 region of flagellin as a PAMP [Smith et al., 2003b] and TLR5-flagellin interaction initiates a 
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pro-inflammatory innate immune response, stimulating cytokine production in antigen presenting 
cells (APCs) [Gewirtz et al., 2001]. Cytokines (IL-12, IL-8) promote adaptive immunity by 
promoting differentiation of naïve T cell to T helper type 1 (Th1) or Th2 cells [Werling, and 
Jungi, 2003; Akira et al., 2001]. Both TLR5 and intracellular receptor NLRC4 play roles in 
cellular immunity. Intracellular flagellin is detected by NLRC4 and induces production of 
Caspase-1, which TLR-induced synthesis of cytokines is dependent upon [Miao, and Rajan, 
2011; Lin et al., 2016].   
Salmonella enterica ser. Typhimurium type 2 flagellin monomer (FliC), a pathogen-
associated molecular pattern (PAMP) and TLR5 agonist, when recombinantly delivered with an 
antigen, increases adaptive immunity and reduces antigen needed per vaccine dose [Honko, and 
Mizel, 2004; Honko et al., 2006]. Flagellin-based fusion proteins incorporating bacterial, 
protozoan, and viral antigens, result in increased serum antibody concentrations in mice [Bargieri 
et al., 2008; Weimer et al., 2009; Song et al., 2009] and has been used safely and effectively in 
human vaccine trials [Tussey et al., 2016]. Flagellin stimulates innate immunity through TLR5 
binding [Hayashi et al., 2001], and associated antigens are subsequently presented and processed 
to the adaptive immune system [Akira et al., 2001]. TLR5 ligands induce Th1 response bias 
[Agrawal et al., 2003], which is associated with less allergenicity or hyperactivity and favored 
for promoting long-term protection.   
Flagellin monomers delivered as recombinant vaccine formulations improve adaptive 
immunity in animal studies [Song et al., 2015c; Monaris et al., 2015; Savar et al., 2014a; Yin et 
al., 2013; Camacho et al., 2011]. Minimal dosage of native FliC required to act upon the innate 
immune system was determined to be as low as 1 – 10 µg in primate studies [Weimer et al., 
2009]. Phase 1 clinical vaccine trials of recombinant flagellin, recombinantly expressed with 
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influenza hemagglutinin, demonstrated low reactogenicity and strong immunogenicity in humans 
[Tussey et al., 2016]. 
	
Fig 2. Flagellin immune stimulation pathway [Miao, and Rajan, 2011].  
Flagellin stimulates cytokine production by two mechanisms: a surface receptor TLR5 and an internal 
pathway by NLRC4. NLRC4 stimulation is associated with apoptosis and is a cell response to flagellated 
intracellular production or infection from the inside the cell.   
 
 Structural properties of flagellin monomer 1.2
Modification of flagellin structure by truncation and insertion of foreign antigenic 
sequence variably affects immunogenicity and reactogenicity in the host. This modular character 
provides a rational basis for vaccine design strategies to target specific or combinations of 
immune pathways leading to host adaptive memory. Flagellin monomer is composed of four 
domains: 1) N- and C-terminal D0, 2) highly conserved D1, 3) D2, and 4) hypervariable D3 
[Yonekura et al., 2003]. TLR5 activation is primarily facilitated by a lateral three α-helices D1 
domain configuration, but C-terminal D0 also facilitates activation, and its removal reduces 
TLR5 activation 1000-fold [Yoon et al., 2012]. The hypervariable D3 domain, which is exposed 
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on the surface of the flagella, is the target of host antibody response [Smith et al., 2015], and its 
modification can tolerate sequence insertion or excision if TLR5-binding D1 domain 
conformation is retained [Yang et al., 2013; Liu et al., 2011]. These modular properties of 
flagellin permit development of strategies to target specific pathways of the immune system 
leading to long-term host immunity.  
A mutation analysis of Salmonella enterica Typhimurium FliC identified a conserved D1 and 
a hypervariable D3 region [Smith et al., 2003a]. Crystallographic studies further characterized 
flagellin by identifying the conserved D1 regions to be an N-terminal α-helix, a C-terminal α-
helix, and a β-hairpin, which bind TLR5 when configured laterally [Yoon et al., 2012]. 
Truncated versions of flagellin monomer FljB, removing the D2 and/or D3 or terminal D0 
regions, modify host immune response compared to non-truncated FljB, allowing for reduction 
in reactogenicity while retaining immunogenicity [Song et al., 2015a]. Recombinant FljB with 
missing D0 regions and C-terminal attached influenza hemagglutinin, may lower reactogenicity 
of FljB construct while retaining ability to stimulate a strong adaptive immune response [Song et 
al., 2015a]. Additionally, the hypervariable D3 region can tolerate excision and modification and 
is not required for inflammatory activity in in vivo models [Donnelly, and Steiner, 2002].  
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Fig. 3. Full-length and truncated flagellin [Lu et al., 2013]  
Full-length FliC model on the far left shows the full native structure of FliC, and its major subunits with 
TLR5 activating region highlighted. The middle model represents a FliC monomer with the C-terminal D0 
region cleaved, which as mentioned above, is associated with an intracellular NLRC4-activating region. 
This cleavage on the C-terminal D0 domain is typical during production because it is unstable and subject 
to proteolysis and the lack of D0 region on the C-terminal reduces adaptive response substantially. 
 
Recombinant flagellin has shown variability in TLR5 activation. Maximal bioactivity at 
50% (EC50) ranges between 20 pM and 2 nM [Skountzou et al., 2010; Saha et al., 2007; Mizel et 
al., 2003; McDermott et al., 2000; Andersen-Nissen et al., 2005]. It is suggested that some full-
length flagellin may be cleaved prior to or when injected into mice and groups are working to 
address TLR5-activation variability by stabilizing the D0 region [Lu, and Swartz, 2016]. 
 
 Expression and purification of recombinant flagellin 1.3	
Recombinant production of flagellin-based products in E. coli is favorable because the E. 
coli genome is well characterized, and production is rapid and economical. High cell density and 
flagellin product yield have been achieved using fed-batch fermentation with defined medium 
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[Song et al., 2015a]. Several upstream modifications to E. coli cultivation conditions can be used 
to improve protein expression and recovery: growth medium composition, temperature of 
induction, concentration of IPTG, promoter selection, and antibiotic selection. Fed-batch 
cultivation in E. coli systems has provided cell content yields greater than 100 g dry weight per 
liter [Lee, 1996].  
Purification strategies of recombinant flagellin use some of the following methods: 
affinity-based chromatography, aqueous two-phase extraction (ATPE), precipitation, size 
exclusion chromatography, ion exchange chromatography (AEX), and hydrophobic interaction 
chromatography (HIC). VaxInnate purified recombinant flagellin-antigen chimeric proteins at 
small and industrial scale using a combination of PEG precipitation, ATPE, Tangential Flow 
Filtration (TFF), cation exchange chromatography, HIC, and refolding [Song et al., 2010].  
Endotoxin removal methods for recombinant protein manufacturing in the pharmaceutical 
industry are diverse, as each technique is not broadly applicable. Techniques are adapted based 
on target protein characteristics and application [Magalhães et al., 2007]. Development of a 
purification strategy for recombinant protein recovery accounts for target protein properties such 
as the net charge of protein and hydrophobicity, the affinity of the target protein to 
chromatography substrate or media, and aggregation. Since endotoxin carries a net negative 
charge, a positive-charged protein has greater affinity for endotoxin, which may be modified by 
pH, temperature, ionic strength of the solution, and solvent/detergent selection [Fiske et al., 
2001]. Purifying conditions contribute to the effectiveness of endotoxin removal techniques.  
Aqueous two-phase extraction (ATPE) is a low-cost technique for large-scale endotoxin 
removal from protein. TritonX-114, a detergent, dissociates tightly bound endotoxin molecules 
from protein, collecting in the detergent phase, while proteins migrate to the aqueous phase. This 
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technique has been demonstrated for use in large-scale (200-500 mg protein) purifications with 
99% endotoxin reduction and 90% protein recovery [Liu et al., 1997]. Alterations of this 
approach use polyethylene glycol (PEG), eliminating the need for temperature modifications to 
separate phases [Song et al., 2010].    
Immobilized Metal Affinity Chromatography (IMAC) is appropriate for purifying from 
crude cell extract, achieving >80% purity from one chromatographic step. Histidine-tagged 
proteins are also not FDA-approved for use in humans as nickel from purifying columns and 
may contaminate the product, but may be appropriate for research-grade material. A refolding 
step, coupled with an immobilized chromatography step, is often used with IMAC.   
Determining simplest combination and order of purification procedures to meet target 
outcome measures is unique for each protein, and requires empirical investigation. The intended 
use of a final product will inform purification strategy. Research-grade products, which are 
suitable for in vitro and animal testing, differ in standard from vaccine-grade products and 
involve alternate processing steps.   
 
2 SPECIFIC AIMS AND HYPOTHESES 
 Aim 1: Production and analyses of recombinant native FliC 2.1	
Aim 1 proposes production of native FliC at small-scale to characterize a crude 
preliminary product, develop production and analytical protocols, and determine in-process 
factors related to outcome. In this aim, Target Product Profile (TPP) will be defined, and flask 
and bioreactor expression, purification, and analytical protocols developed resulting in a crude 
product, will be compared to commercial benchmark.  
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Hypothesis 1: Development of improved production method can permit process evaluation of 
for recombinant flagellin products and enhance outcome measures. 
 
	
Fig. 4. Aim 1- Native FliC production workflow.  
Native FliC expression and purification process will be developed using non-denaturing methods and 
analyzed for Target Product Profile (TPP), defined by a commercial standard. 
 
 Aim 2: Demonstrate rational basis and verify platform character of Synthetic FliC by 2.2
streamlining in silico design and purifying Synthetic FliC fusion proteins 
 Aim 2 proposes a framework for rational design and characterization of FliC fusion 
platform using computational tools and inserting RSV antigens in non-conserved regions of 
Synthetic FliC. Vaccine design and process development strategies use computer-based methods 
Native	FliC	
	soluble	
fraction	
PEG	precipitation	
2-phase	separation	
Nickel	column	
Endotoxin	Column	No	Endotoxin	Column	
Outcome	analysis:	Endotoxin	level,	purity,	scale,	and	cost			
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to identify product characteristics and target product outcome. In silico prediction of epitope 
conformation, TLR5-binding region, and physiochemical features will be evaluated for a series 
of flagellin-based RSV fusion constructs and tested in vitro.   
 
 
Hypothesis 2: Synthetic FliC, with multiple cloning sites on the terminal ends and hypervariable 
region used with systematic and rational approach, will help product developers design bioactive 
recombinant FliC-fusion proteins more rapidly and of better quality. Synthetic FliC will be 
shown to be compatible with a flexible and universal/standardized manufacturing process with 
higher success rates, and may expose some underlying structure of the vaccine process 
development or design structure itself.   
 	
3 PRODUCTION AND CHARACTERIZATION OF NATIVE FLIC 
 Introduction 3.1
3.1.1 Flagellin production 	
Bacterial flagellin is used as an immune stimulant in the development of therapeutic 
drugs and vaccines. Despite commercial availability of flagellin, studies requiring large 
quantities for animal models must be prepared in-house, as commercial products are costly. 
Quantities of flagellin needed per-dose in therapeutic drug development ranges from 0.01 µg to 1 
mg and mouse studies typically require between 0.3 µg – 10 µg flagellin-fusion protein per dose. 
Highly pure and inexpensive production of flagellin at large-scale is needed. Flagellin 
purity requirements vary among research projects and some require very high purity from 
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endotoxin and host cell proteins, as in vitro and in vivo tests performed are sensitive to 
interfering effects from cell surface receptors other than TLR5. Host immune receptors such as 
TLRs besides TLR5, RLRs, and NLRs are involved in immune responses and may activate the 
same pathways or result in physiological outcomes similar to TLR5 [Haile et al., 2015; Creagh, 
and O’Neill, 2006]. Commercial flagellin manufacturers produce flagellin in Eukaryotic 
expression systems as an alternative to E. coli production, due to presence of LPS in E. coli 
preparations. LPS stimulates TLR4, and concentrations as low as 0.002 ng/mL activate dendritic 
cells [Schwarz et al., 2014]. Flagellin purity from host and cellular components may not be 
needed for some research and TLR5 stimulating effect is in itself sufficient.  
Commercial flagellin can be produced in two ways: shearing and purification of flagella 
from cultured flagellated organism such as Salmonella Typhimurium or expressed recombinantly 
in bacterial or Eukaryotic systems. Sheared flagellin can achieve yields as high as 1 g/L culture 
[Oliveira et al., 2011], but may be difficult to produce in very high yields and varies by batch. 
Invivogen achieves the highest purity among sheared FliC products (FliC Ultrapure) at >95% 
purity from extraneous protein and endotoxin levels <0.05 EU/µg. Endotoxin levels as 
determined by TLR4 assay, have been reported for sheared flagellin when purified using 
polymixin-B columns (unpublished Gewirtz lab), but yields result in around 2 mg/L. Flagellin 
fusion proteins produced recombinantly can be recovered at yields as high as 3.7 - 10 g/L at 
>90% purity from host cell proteins and <0.05 EU/µg, from batch-fed fermentation [Pierce et al., 
2015] using insoluble recovery methods. Research groups produce highly pure recombinant 
FliC-antigen fusion proteins in E. coli in small-scale for use in animal trials with endotoxin 
levels <0.05 EU/µg [Lin et al., 2016; Bargieri et al., 2008; Lockner et al., 2015]. Eukaryotic 
expression, through baculovirus-insect cell expression has been used to produce flagellin at small 
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scale with no detectable endotoxin [Bennett et al., 2015; Zhu et al., 2016] and expression in 
HEK293 has been demonstrated [Taherkhani et al., 2014], which Invivogen is using for 
recombinant FliC production with endotoxin <0.005 EU/µg protein. 
LifeSpan Biosciences Recombinant FliC 6xHis (LS-G3953) is a commercial product 
most similar to our intended product. Purity, endotoxin level, cost, and scale will serve as a 
benchmark and define our Target Product Profile. Therefore, the TPP for our Recombinant FliC 
is defined as: >95% purity from extraneous protein determined by SDS-PAGE, Endotoxin levels 
below 0.01 EU/µg protein determined by 3-point LAL chromogenic kinetic assay, demonstrates 
TLR5-binding activity, scalable production process used, and cost to produce is <20% of current 
market price. Final formulated Native FliC product will be compared analytically to commercial 
standard to determine if TPP was met.        
         
Table 1. Comparison of commercial flagellin (3.29.18) 
Product Purity Endotoxin 
(EU/µg) Mass (µg) Cost ($) 
Invivogen     
FLA-ST (Sheared)- Standard ~10%  1-10 100 244 
FLA-ST (Sheared) Ultrapure >95%  <0.05 50/10 496/199 
Recombinant-standard 
(Eukaryotic expression 
–HEK293) 
n/a <0.005 
50/10 617/248 
Recombinant- Vaccigrade 
(Eukaryotic expression 
–HEK293) 
n/a <0.005 
50 1392 
Adipogen     
FliC (sheared) >90% <0.1 100 215 
FliC- high purity (sheared) >95% <0.01 3x10/10 320/160 
Recombinant- NLRC4 
mutant (truncated part of C-
terminal D0 region) + 6xHis 
>95% <0.01  
3x10/10 400/180 
Recombinant- full length + 6x 
His 
>95% <0.01  3x10/10 400/180 
Recombinant TLR5 mutant 
(does not bind as TLR5 
ligand) + 6x His 
>95% <0.01  
3x10/10 400/180 
Novus     
Sheared- discontinued     
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Recombinant- 6xHis  >95% <1  10/50/100/1000 3.2 79/179/329/2000 
Flagellin TLR5 ligand (no 6x 
His tag) 
n/a n/a 10 289 
Sigma     
Flagellin (FliC)- no tag – 
endogenous 
>95% <0.01 10 188 
LifeSpan Biosciences     
FliC- no tag (LS-G3927) >90% <0.1 100 315 
FliC- no tag (LSG3883) >95% <0.01 10 265 
FliC- recombinant  His tag (LS-
G3953) 
>95% <0.01 10 285 
FliC-Recombinant NLRC4 
mutant 6xHis (LS-
G3955) 
>95% <0.01 
10 285 
FliC-Recombinant TLR5 
mutant 6xHis (LS-
G3956) 
>95% <0.01 
10 285 
FliC-Recombinant (C-terminal 
6xHis) (LS-G18909) 
Different species- 
ATCC68169/UK-1 
>95% n/a 
20/100/1mg 195/255/1260 
FliC- no species name – no tag 
(LS-G41471) 
>90% n/a 50 305 
FliC- E. coli – no tag (LS-
G51774) Met1-Ser287 
>95% n/a 20 295 
 
 Materials and Methods 3.3
 
Cloning Native FliC into pJ404 
pETBlue1® vector with Salmonella enterica ser. Typhimurium Native FliC was isolated 
from E. coli, confirmed by DNA sequencing, and used as a template to subclone into expression 
vectors pJ404 and pET28a-LIC. Native FliC insert was prepared by amplifying Salmonella 
Typhimurium LT2 Native FliC PCR insert with primers adding NcoI and BamHI (Table. 2) 
restriction enzyme sites for cloning and in frame expression with 6x Histidine tag in pJ404. 
pETBlue1-FA4 Native FliC plasmid was used as template in 2 –step PCR with annealing 
temperature at 49°C for first 5 cycles, followed by 30x cycles at 56°C. All dissociation and 
elongation steps were 95°C and 72°C, respectively with 1.5 min per cycle elongation time. PCR 
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insert product and pJ404 vector were each digested with NcoI and BamHI for 1 h at 37°C and 
insert and 3000 bp empty pJ404 band purified by Qiagen Gel Extraction kit. Insert and vector 
were ligated using T4 ligation kit (ThermoScientific) by incubating at room temperature for 1.5 h 
and purified by Qiagen MinElute Cleanup kit. Electroporation transformation was performed 
using BioRad MicroPulser by standard BioRad protocol with 1 mm cuvettes at EC1 setting in 
electrocompetent E. coli BL21, recovered with room temperature SOC, and incubated for 1 h at 
37°C and 250 RPM shaking. 25µl, 100µl, and 500µl recovered mixture was dispersed on 50 
µg/mL carbenicillin selective LB agar plates and incubated overnight at 37°C.   
           
 
Table 2. Native FliC PCR primers 
Primer Name Sequence Restriction enzyme 
cut site 
b.p. 
FA4 Forward primer GCAACCATGGCACAAGTCATTAATACA NcoI 27 
FA4 Reverse Primer GGTAGGATCCACGCAGTAAAGAGAGGA BamHI 27 
 
Colonies were screened by colony PCR using a forward primer specific for Native FliC 
and FA4 reverse primer (Table. 2). Colonies yielding PCR products of expected 1400 bp DNA 
bands were again streaked on 50 µg/mL carbenicillin LB agar plates and tested by colony PCR. 
Colonies with expected bands were cultured overnight in 50 µg/mL, plasmid extracted by 
ThermoScientific Miniprep kit, and sequenced by 3730 Genetic Analyzer at GSU Advanced 
Biotechnology Core. Culture was stored at -80°C as 10% glycerol stocks.     
 
Native Salmonella enterica ser. Typhimurium Flask Expression and Characterization 
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Overnight Native FliC starter culture was used to inoculate 50 mL TB in 250 mL baffled 
flask with 100 µg/mL carbenicillin, shaking at 250 RPM at 37°C and 30°C. Culture was induced 
with 3 mM IPTG after 3 h incubation and samples collected every hour for 8 h for analysis on 
SDS-PAGE. Biphasic Terrific Broth and ECAM (Reisenberg-derived [Riesenberg, 1991] 
minimal media (per L: 7.8 g K2HPO4, 1 g citric acid, 2.33 g (NH4)2SO4, 0.01 g Thiamine HCl, 10 
g glucose, 1.01 g MgSO4, 0.04 g CaCl2, 100 mg ampicillin, and 1 mL trace metal solution (per L: 
5 g EDTA, 10 g FeSO4, 2 g ZnSO4, 2 g MnSO4, 0.2 g CoCl2.6H20, 0.1 g CuSO4.H20, 0.2 g 
Na2MoO4.2H20, 0.1 g H3BO3)) flasks were prepared with 50 mL100 µg/mL carbenicillin agar 
and 12.5 mL 100 µg/mL media according to Tyrell, et al [Tyrrell et al., 1958] and TB biphasic 
flasks inoculated at OD600 = 0.05 with overnight starter culture and shaking at 200 RPM at 37°C 
and 30°C, inducing with 1 mM IPTG during log phase. ECAM biphasic flasks were inoculated at 
OD600 = 1.0 with an overnight starter from 3rd pass adapted glycerol stock and induced with 1 
mM IPTG during log phase for analysis on 4-12% Bis-Tris NuPage SDS-PAGE. 1L of TB in 4L 
flask was inoculated to OD600 0.05 from overnight starter culture, induced in log phase with 1 
mM IPTG for 3.5 h. Cell pellet was collected by centrifugation in 15 mL falcon tube at 10,000 
RPM for 10 min at 4°C and lysed by sonication on ice 3x using 4 second pulses for 20 seconds 
each in the presence of 1x Mini-cOmplete® protease inhibitors in 1g cell wet weight/5mL Lysis 
buffer (50 mM Tris-base, 125 mM NaCl, 4% sucrose, 0.05% TritonX-100, pH 8). Lysate was 
centrifuged at 10,000 RPM for 10 min at 4°C and soluble sample was removed. Pellet was 
washed in 8M urea buffer at pH 4 three times with aggressive sonication in the presence of 
protease inhibitors. Samples were analyzed on 4-12% Bis-Tris NuPage SDS-PAGE gel.          
 
Fermentation expression and characterization 
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E. coli housing pJ404-Native FliC was adapted to ECAM by growing to OD600 = 1 at 
30°C shaking at 250 RPM in 100 mL LB + 100 µg/mL carbenicillin, diluted 1:10 in 100 mL 
ECAM with 100 µg/mL carbenicillin and grown at 37°C shaking at 250 RPM until OD600 
reached 1-1.5. Culture was diluted 1:10 a second time in 100 mL ECAM and cultured for 24 h 
shaking at 225 RPM and 30°C.    
Adapted starter culture was used to seed 10 L batch medium (KH2PO4 2.2 g L-1, Citric 
acid 1 g L-1, (NH4)2SO4, 4.5 g L-1, Trace metal solution 1 ml L-1, Thiamine HCl 10 mg L-1, 
Glycerol 22 g L-1, MgSO4 1 g L-1, CaCl2 40 mg L-1, Antifoam 204 75 µL L-1, Ampicillin 100 mg 
L-1) in B. Braun (Sartorius) Biostat® 20C stirred tank bioreactor at 35°C, pH maintained at 7.0 
with 2 M NaOH, and 28 % max pO2 concentration. Feed medium (KH2PO4 1.5 g L-1, 
(NH4)2HPO4 10 g L-1, NaH2PO4 4 g L-1, (NH4)2SO4 5 g L-1, Citric acid 1 g L-1, Trace metal 
solution 6 ml L-1(EDTA 5 g L-1, FeSO4 ·7H2O 10 g L-1, ZnSO4 ·7H2O 2 g L-1, MnSO4 ·H2O 2 g 
L-1, CoCl2 ·6H2O 0.2 g L-1, CuSO4 ·H2O 0.1 g L-1, Na2MoO4 ZnSO4 ·2H2O 0.2 g L-1, H3BO3 0.1 
g L-1), Thiamine HCl 50 mg L-1, Glycerol 200 g L-1, MgSO4 4.6 g L-1, CaCl2 2 mg L-1, Antifoam 
204 75 µL L-1, lactose 10 g L-1) was added when glucose was exhausted at OD600 = 30 and 
adjusted according to glucose consumption. The culture was induced after three hours of feed at 
OD600 = 60 with 1.7 mM IPTG. 5g Yeast Extract was pulse-fed 30 min after induction and 10 
mL samples collected hourly. Dissolved oxygen (DO) was maintained at 35% by cascade control 
with agitation (min value 260 RPM and max 450 RPM). Harvest 1 (3.7 L) was removed 3 h after 
induction and Harvest 2 (7.8 L) removed after 5 h and samples were analyzed for plasmid loss by 
dilution with filtered ddH20 and plated on LB plates without antibiotics. Ten colonies from plates 
were selected at random and streaked on 100 µg/mL carbenicillin plates and incubated at 37°C 
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for two days.  Hourly timecourse samples were analyzed on 4-12% Bis-Tris NuPage SDS-PAGE 
and Western blot with anti-FliC (Invivogen) (1:2000).  
 
Purification, formulation, and evaluation 
Native FliC E. coli cell paste from 50 mL baffled flasks induced with 3 mM IPTG was 
disrupted by sonication on ice 3x by 4 second pulses for 20 seconds in the presence of Mini-
Complete protease inhibitors in 1g cell wet weight/5mL Lysis buffer (50 mM Tris-base, 125 mM 
NaCl, 4% sucrose, 0.05% TritonX-100, pH 8), incubated at 30°C for 1 h, and centrifuged at 
10,000 RPM at 23°C for 10 min. PEG 3350 was added to the supernatant to 14% (w/v), stirring 
at room temperature, and centrifuged at 10,000 RPM for 60 min at 15°C. Pellet was resuspended 
in Resuspension buffer (20 mM Tris, 100 mM sucrose, pH 8) and centrifuged at 10,000 RPM for 
60 min at 15°C. At room temperature, supernatant was treated with 1% (v/v) TritonX-114, 
stirred for 15 min and 5% (w/v) PEG 3350 added and stirred for 15 min, followed by 3 h at 
10,000 RPM centrifugation and 24oC. Aqueous layer was filtered through 22 µm syringe, 
dialyzed with binding buffer (5 mM imidazole, 20 mM sodium phosphate, 0.5 M NaCl, pH 7.4) 
overnight with Spectra/Por MW 3,500 at 4°C, applied to 1 mL nickel column (GE HisTrap) at 1 
mL/min, and eluted with 5 CV elution buffer (20 mM sodium phosphate, 100 mM imidazole, 0.5 
M NaCl, pH 7.4) at 0%, 20%, 40%, 60%, 80%, and 100% step gradient. Flowthrough and 0% 
step gradient fraction were combined and half treated with Pierce High Capacity Endotoxin 
Removal Spin Column (cat # 88274), following manufacturers protocol. Samples treated and 
untreated with endotoxin column were dialyzed with PBS and lyophilized overnight at -100°C 
(Virtis BT3.3 EL Tabletop Lyophilizer). Samples were quantified by Bradford assay, purity 
evaluated by 4-12% Bis-Tris NuPage SDS-PAGE gels and ImageJ®, and Western blot was 
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performed using anti-FliC (1:2000) and secondary anti-mouse HRP (1:2000). Bands from the 
SDS-PAGE gel were extracted and analyzed by LC-MS/MS provided by Dr. George Wang in 
the Chemistry Department. Endotoxin concentration was assessed by 3-point Charles River 
Kinetic Limulus Amebocyte Lysate Endosafe Endochrome assay (R1708K).  
 
 Results 3.4
3.4.1 In silico properties 	
Table 3 summarizes the primary structural character of Native FliC as determined by 
ExPASy Prot Param® and SOLPro. SOLPro predicted a 0.65 probability of Native FliC soluble 
fraction expression when overexpressed. Native FliC was predicted to have in vitro stability, 
with instability index below 40, suggesting stability at room temperature. 
 
Table 3. In silico properties of Native FliC 
Property Value 
MW (kDa) 52.8 
pI 5.07 
Instability index 24.51 
Probability of solubility in E. coli when 
overexpressed 
0.65 
 
3.4.2 Cloning 	
DNA sequence of Salmonella enterica Typhimurium LT2 flagellin was confirmed (Fig. 
5). Growth in BL21 (DE3) was slow when housed and expressed with pET28a-LIC or 
pETBlue1. Both plasmids failed to overexpress in LB or after adaptation to minimal media upon 
fresh transformation, prompting the selection of pJ404 as an expression vector (Table. 4). 
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Fig. 5. Native FliC alignment in pETBlue1 vector.  				
Table 4. Recombinant FliC Constructs 
 
 
Native FliC insert was amplified from pETBlue1® vector with PCR primers adding N-
terminal NcoI and C-terminal BamHI, yielding an insert product ~1500 bp (Fig. 6A). pJ404 
expression vector was prepared by removal of Synthetic FliC sequence (1290 bp), digesting with 
restriction enzymes NcoI and BamHI and analyzed on 1% agarose gel (Fig. 6B). Double digested 
pJ404 (~4000 bp) band was extracted and ligation reaction yielded 14.7 ng/µl DNA with 260/280 
of 3.72 of 1:7 insert to vector ratio sample after MinElute Reaction cleanup kit. Transformation 
on 50 µg/mL ampicillin selective plates yielded 2, 5, and 2 colonies on 25 µl, 100 µl, and 500 µl 
Name Description MW (kDa) Vector 
Antibiotic 
Resistance Promoter Organism 
Expressio
n 
Native 
FliCPet 
Native FliC in 
pETBlue 53 pETBlue1 Ampicillin T7 
BL21 
(DE3) No 
Native 
FliC6x C-term His tag 53 pJ404 Ampicillin T5 BL21 Yes 
Native 
FliCKan
6x 
C-term His tag 53 pET28a-LIC Kanamycin T7 BL21 (DE3) No 
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plating volumes, respectively. Colonies from each plate were screened by colony PCR, resulting 
in banding from 2 colonies in each 100 µl (Fig. 6C, Lanes 3 and 4) and 500 µl (Fig. 6C, lanes 5 
and 6) volume plates. Colony showing the greatest growth (from 100 µl plate) were streaked 
again onto 50 µg/mL LB ampicillin agar plate and confirmed by colony PCR. DNA sequencing 
confirmed in-frame sequence.   
	
Fig. 6. DNA cloning and colony PCR confirmation. 
Amplification of Native FliC gene from pETBlue1® and confirmation of recombinant pJ404-FliC clone. 
(A) PCR product of Native FliC with NcoI and BamHI restriction enzyme sites added to terminal ends. 
(B) Digested NcoI and BamHI pJ404 vector purified from E. coli BL21 (C) Colony PCR from 6 
transformation plate colonies.      
 
3.4.3 Flask characterization 
Native FliC construct was expressed and evaluated in 250 mL and 4L flasks using varied 
culturing conditions. All biphasic and baffled flask induction resulted in overexpression and 
density as high as OD600 of >35 was achieved in biphasic TB flasks (Fig. 7A), resulting in cell 
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0.33 g cell wet weight per 12.5 mL TB in 50 mL TB agar. Biphasic ECAM cultures induced with 
1 mM IPTG after 3 h growth, resulted in induction as indicated by Coomassie stain (Fig. 7B). 
Baffled TB flasks achieved OD600 ~ 20 after with recombinant Native FliC produced as fusion 
protein with high accumulation after 1 h when induced at 37°C and moderate accumulation at 
30°C after 3 h induction, as indicated by Coomassie stain (Fig. 7C). 1L TB culture induced with 
3 mM IPTG at 37°C showed expression with Native FliC migrating to the soluble (79%) and 
insoluble (21%) fractions (Fig. 8).        
 
	
Fig. 7. Timecourse analysis of recombinant Native FliC. 
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Timecourse analysis of recombinant Native FliC in E. coli. Optical density measurements at 600 nm from 
0 to 25 h during Native FliC expression under biphasic and baffled shake flask conditions using TB and 
ECAM media at 37°C and 30°C. Flask characterization of native FliC. (B) Biphasic 50 mL agar and 12.5 
mL ECAM, induced by 1 mM IPTG at 37°C for 3h and uninduced at 10 µg soluble fraction per lane 
analyzed. (C) Samples collected from 0 – 8 h after induction 50 mL TB baffled flask at 37°C and 30°C, 3 
mM IPTG at 3 h after inoculation, were analyzed on Coomassie blue stained 4-12% Bis-Tris NuPage 
SDS-PAGE gel.  
 
    
	
Fig. 8. SDS-PAGE analysis of Native FliC expression and solubility 
(A) 1L TB Culture was induced by 3 mM IPTG at 37°C for 3h, soluble and insoluble fractions separated, 
and loaded at 10 µg per lane.  
 
3.4.4 Production of Native FliC in bioreactor 
The growth of culture reached log phase in batch after 12 hours, around the point of 
glucose exhaustion. Feed media began at OD600 = 30 and density plateaued between 45-60 hrs 
after induction and glucose concentration reached 0 g/L twice after feed, but started to 
accumulate (Fig. 9). OD600 at Harvest 1 (3h post-induction) was 58 and Harvest 2 (5h post-
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induction) was 60. Soluble timecourse of bioreactor samples showed expected 52 kDa band 
appear between 2-3 h post-induction until final 5 h Harvest 2 (Fig. 10 A and B). Harvest 1 
yielded 133 g and Harvest 2, 390 g for a total of 523 g wet weight, averaging 45 g/L. Only 1.5 L 
Feed media was added, with a final conditioned medium volume of 11.5 L (Table 5). From 10 
colonies capable of growth on non-antibiotic plates, 8 and 4 colonies from Harvest 1 and Harvest 
2, respectively, grew on selective plates (Table 5).     
 
	
Fig. 9. Fermentation timecourse growth curve 
Timecourse of OD600 and feed rate percent of E. coli BL21 expressing native FliC in pJ404 in 12 L 
fermentation. Harvest 1 was removed at 3h post induction and Harvest 2, 5h.  
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Fig. 10. SDS-PAGE and Western blot of fermentation timecourse 
Evaluation of 12L fermentation after induction with 1.7 mM IPTG induction of soluble Native FliC 
fraction on (A) SDS-PAGE gel and (B) Western blot with 1:2000 anti-FliC antibodies 
 
Table 5. Native FliC fermentation yield and plasmid loss 
 
Harvest 
 
Wet weight (g) 
 
Media (L) 
 
g/L 
Colony growth on carbenicillin 
agar (%) 
Harvest 1- (3 hours) 133 3.7 36 80 
Harvest 2- (5 hours) 390 7.8 50 40 
Total 523 11.5 45 - 
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3.4.5 Purification 	
Cell lysate from 1 L TB induced with 3 mM IPTG was clarified by PEG precipitation and 
2-phase separation under native conditions. PEG precipitation retained most of the Native FliC 
during the first precipitation step, but a significant proportion was lost during the second 
resuspension step. The 2-phase separation procedure, performed on the PEG precipitation 
resuspension supernatant, clarified the sample to 90%, but with a 30% reduction in FliC. Further 
clarification of 2-phase aqueous phase sample using nickel column did not improve clarity and 
sample eluted in the flowthrough and wash fractions, suggesting poor affinity (Fig. 11 A and B, 
and Table 6).  
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Fig. 11. SDS-PAGE and Western blot of purification steps 
Non-denaturing Native FliC PEG precipitation, 2-phase separation, and Nickel column chromatography 
of 1.7 g paste from 50 mL TB baffled flask induced with 3 mM IPTG. (A) SDS-PAGE- 10 µg per lane, 
and Nickel column 1.5 µg per lane, (B) Western blot with 1:2000 anti-FliC  
 
 
Table 6. Native FliC Protein Summary Table- non-denaturing soluble 
 
In-process sample 
Fraction 
volume (mL) 
Total protein 
(mg) 
Percent purity 
(FliC) 
Total 
FliC (mg) 
Endotoxin 
(EU/µg) 
Crude extract* - - - - - 
1st Centrifuge Pellet - - - - - 
1st Centrifuge Supernatant* 10 62.1 10 6.2 - 
PEG precipitation- pellet* 10 17 38 6.2 - 
PEG precipitation- supernatant 9.5 41 0 0 - 
Resuspension pellet 1 4.4 30 1.1 - 
Resuspension supernatant* 10 13 40 5.2 - 
2-phase separation- aqueous 
phase* 
7.5 3.6 90 3.24 - 
2-phase separation- Detergent 
phase 
- - - - - 
Nickel column (flowthrough)* 8 0.8 92 0.74 - 
Buffer Exchange* - - - - - 
Lyophilization/reconstitution* 3 0.68 92 0.63 >0.15 
Endotoxin column* 3 0.54 92 0.49 0.037 
* expected fraction for FliC  
 
3.4.6 Product evaluation 	
Nickel column flowthrough sample was evaluated for purity and integrity for final buffer 
exchange, lyophilization, and reconstitution processing steps and compared to recombinant 
LifeSciences Bio Native FliC. Purity and integrity were consistent throughout final steps. The 
band from LifeSciences Bio FliC ran a few kDa above our recombinant product.  
LC-MS/MS was performed on four bands cut from the SDS-PAGE gel, but only three 
had matches to a database. The first band above 65 kDa in the lyophilized/resuspended sample 
was indeterminate and did not match the database. Band 1, the target band of purification 
product (50 kDa), matched Salmonella enterica Typhimurium LT2 with 46.5% coverage. Two 
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other E. coli proteins were identified in this sample shared similar molecular weights. Band 2, 
running below the main target band, was identified as Salmonella Typhimurium strain LT2, but 
N-terminal coverage from was not complete. Band 2 co-migrated with an E. coli protein of lower 
MW (44.8 kDa). LifeSpan BioSciences recombinant FliC product was identified as Salmonella 
Typhimurium strain LT2 and had greater coverage on the N-terminal end than bands 1 and 2. 
Band 3 co-migrated with the same host cell protein E. coli band found with Band 2 (Fig. 12).        
	
Fig. 12. SDS-PAGE and LC-MS/MS analyses SDS-PAGE	 and	 LC-MS/MS	 of	 extracted	 Native	 FliC	 bands.	 Comparison	 of	 1	 μg	 lyophilized	 and	reconstituted	FliC	to	LifeSciences	Bio	FliC.		
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Endotoxin concentration was measured by LAL kinetic assay with a threshold value of 
0.3 OD405 (Fig. 13). Native FliC sample treated with endotoxin column resulted in an endotoxin 
concentration of 20.2 EU/mL or 0.037 EU/µg Native FliC protein. Native FliC not treated with 
endotoxin column did not fall within the linear range of the LAL and was >50 EU/mL. From 
0.68 mg, 0.54 mg was recovered from endotoxin column, representing a 20% loss in protein.   
	
Fig. 13. LAL kinetic chromogenic endotoxin assay 
 
 Discussion 3.5	
Characterization of scalable recombinant Native FliC production, definition of TPP, and 
comparison of our crude product to commercial standard was achieved in this study. A 
preliminary production process and analytical procedures were defined, allowing future 
systematic evaluation, characterization and improvement of the production process, and scale-up 
of Native FliC products.  
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Native FliC, originally housed in T7 expression vector pETBlue1®, failed to overexpress in 
flask or bioreactor. DNA sequencing was performed to confirm in-frame Native FliC, and 
compared to Salmonella Typhimurium strain LT2 by BLAST showing 100% homology (Fig. 5). 
Native FliC sequence in pETBlue1® vector was used as a template for cloning FliC into pET28a-
LIC, a T7 expression vector with Kanamycin resistance gene and pJ404, a T5 expression vector 
with Ampicillin resistance gene. Native FliC was cloned into pET28a-LIC and confirmed by 
DNA sequencing but failed to express when induced at varied IPTG concentrations in standard 
flask growth conditions. Synthetic FliC, housed in pJ404, previously showed consistent 
induction in flasks with various antigens and modifications and considered to be robust and 
appropriate for Native FliC expression. Synthetic FliC was removed from pJ404, and replaced by 
Native FliC PCR insert with compatible restriction enzyme sites (Fig. 6). These results suggest 
that the T7 promoter systems or vectors used did not provide reliable expression, and that the T5 
pJ404 vector system yielded reliable overexpression.  
Overexpression by IPTG was confirmed in baffled, biphasic, and standard flasks at 
different volumes and temperatures in Terrific Broth or ECAM minimal media, suggesting 
adaptable E. coli and consistent overexpression in varied growth conditions (Fig. 7). 
Overexpression in high cell density (OD600 = 43) was achieved in biphasic TB and ECAM flasks 
(Fig. 7A, B) suggesting the potential for large-scale growth and overexpression. At 37°C in 
baffled shake flasks, the greatest relative protein concentration in lysate was seen around 2 or 3 h 
post-IPTG induction and steady expression after 4 h at 30°C (Fig. 7C). In 1 L TB shake flask, 
Native FliC was expressed at a total 4:1 soluble to insoluble ratio, with insoluble FliC in a purer 
form (Fig. 8). Typical percent target protein in overall protein was around 10-15% in flasks. 
Insoluble pellet was washed three times in denaturing urea to analyze the sample and will have 
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likely lost product, but represents a rapid purity increase early in processing steps and supports 
the universal application of flagellin-based product insoluble recovery as previously detailed 
[Pierce et al., 2015]. In 12L bioreactor, grown at 35°C, expression was seen after 0.5 h, and 
increased until final 5 h Harvest (Fig. 10). Native FliC bioreactor overexpression was not as 
pronounced as flask overexpression or previously reported bioreactor flagellin fusion protein 
overexpression, which may be the result of plasmid loss (Table 5). Both the 3 h and 5 h harvests, 
together, resulted in 523 g packed wet weight. These results confirm robust overexpression at 
flask scale and moderate expression in fermentation vessels. Future work may determine the 
limitations of the pJ404 T5 promoter and ampicillin with the expression of this construct and 
consider whether a T7 and/or a more stable antibiotic such as Kanamycin may be more 
appropriate.    
Soluble recovery from 1L TB induced with 3 mM IPTG in non-denaturing conditions 
using PEG precipitation, 2-phase separation, and nickel column purification, resulted in 540 µg 
~92% pure Native FliC and 0.037 EU/µg protein per 2 g cell paste (Table 6). 2-phase separation 
step, intended to remove endotoxin only, typically has ~80-90% protein recovery. Under these 
conditions, rather, 2-phase separation lost 70% protein, but resulted in 3.6 mg of 90% pure FliC 
(Fig. 11). Subsequent nickel column purification of Native FliC under these conditions may not 
be useful, as product elutes with the flowthrough and wash fractions. Early processing steps 
lysing, PEG precipitation, and 2-phase separation were repeated twice with one yielding similar 
90% purity after 2-phase separation, and the other not selectively recovering FliC. These results 
suggest that early processing and purification steps, without chromatography, have potential to 
recover a considerable amount of Native FliC with moderate purity and may be treated further 
with additional clarification steps. Nickel chromatography was not productive and was attempted 
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under different conditions and imidazole concentrations for the soluble sample. His-column 
purification under denaturing conditions yielded better results from the fermentation paste, but 
was inconsistent and elution often occurred under very low imidazole concentrations (5 – 10 
mM).       
Nickel column elution flowthrough was treated with endotoxin column, lyophilized, and 
resuspended in endotoxin-free water and evaluated by SDS-PAGE, LC-MS/MS, and compared 
to LifeSpan BioSciences FliC. SDS-PAGE and densitometry analysis evaluating extraneous 
banding, suggest ~92% purity of target band ~50 kDa. Extraneous bands on SDS-PAGE were 
evaluated by LC-MS/MS and suggest lower band to be FliC, but running at less than 50 kDa, 
which may be a partially degraded FliC product. The LifeSpan BioSciences commercial standard 
runs above 50 kDa compared to our product, which may be the result of less loading protein.  
LifeSpan BioSciences FliC was resuspended from lyophilized form according to manufacturers 
instruction and is targeted to have 1 µg/10µl, but band is less dense than 1 µg of our recombinant 
FliC. LC-MS/MS did not achieve complete coverage for excised bands, but did reveal 
contaminating proteins co-migrating with target proteins. The coverage did suggest that all 
products maintained at least half of their C-terminal D0 regions, which is sensitive to proteolysis. 
Endotoxin levels in Native FliC nickel column flowthrough were higher than 150 EU/µg, but 
when treated with endotoxin column, resulted in 0.037 EU/µg and 20% loss of protein.     
Preliminary data using fermentation paste purified by PEG precipitation, 2-phase 
separation, and Nickel column treatment under denaturing conditions yielded >95% purity 225 
µg/2 g cell paste, and 0.07 EU/µg FliC, representing 53 mg purified FliC at scaled purification, 
but sample was not treated with refolding step and TLR5-binding affinity was not evaluated. 
Endotoxin levels are also higher than most recombinant flagellin commercial products. But even 
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with inefficient recovery at refolding step and an additional endotoxin removal step, this method 
may have potential to recover pure and bioactive product. 
Compared to LifeSpan BioSciences product, our recombinant FliC does not achieve the 
same purity as from host cell protein and endotoxin (Table 7). Host cell protein and endotoxin 
contamination would improve with a chromatography step. Chromatography in this study was 
not selective. Our Native FliC product compares to several low-grade flagellin products with 
higher purity and/or lower endotoxin levels (Table 8).  
  
Table 7. Comparison of our recombinant Native FliC to LifeSpan BioSciences  
  
 
 
Table 8.  Comparison of low-grade flagellin products   
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4 DESIGN, PRODUCTION, AND CHARACTERIZATION OF SYNTHETIC FLIC-
RSV SERIES 
 Introduction 4.1
4.1.1 RSV background 
Respiratory Syncytial Virus (RSV), a member of the Pneumoviridae family, is a primary cause 
of acute lower respiratory tract infections (ALRTI), leading to hospitalizations and deaths in 
infants and immunocompromised patients. Only two FDA-approved treatments for RSV are 
currently available: 1) administered neutralizing monoclonal antibodies palivizumab (Synagis®; 
MedImmune) targeting conserved RSV Fusion (RSVF) glycoprotein antigenic site II (aa 255 – 
278) and 2) ribavirin, an antiviral used to treat only severe RSV cases. Palivizumab is effective 
in preventing and treating short-term RSV disease in infants [Scott, and Lamb, 1999], whereas 
ribavirin efficacy data is limited [Ventre, and Randolph, 2007]. Palivizumab and ribavirin are 
considered cost-prohibitive in low and middle-income countries, further highlighting the need for 
long-term and low-cost preventative interventions.  
RSV vaccine candidates are in development, but low immunogenicity, high 
reactogenicity, stability, and low recombinant RSVF production yield remain major challenges 
to development and production. Early vaccine trials using formalin-inactivated RSV (FI-RSV) 
failed to induce protection in infants and actually caused vaccine-enhanced disease [Fulginiti et 
al., 1969; Chin et al., 1969; Welliver et al., 1984]. RSV has sophisticated evasion mechanisms 
which include: modulation of signaling pathways such as Toll-like receptors (TLRs), NOD-like 
receptors (NLRs), and RIG-I-like Receptors (RLRs) [Zeng et al., 2012]. RSV also elicits 
unfavorable Th2-bias, promoting hyperinflammatory response [Becker, 2006] and large-scale 
production of recombinant RSVF, a leading target for RSV vaccine development, favors a less 
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immunogenic post-fusion conformation, resulting in aggregation and reduction of yield [Begoña 
Ruiz-Argüello et al., 2002].  
RSV subunit vaccines show promise in addressing challenges associated with 
immunogenicity, reactogenicity, and production yields [Jaberolansar et al., 2016]. Two epitopes, 
RSV attachment glycoprotein (RSVG) conserved cysteine-rich region (GCRR, aa 164 – 176) and 
palivizumab-binding RSVF antigenic site II, are currently being evaluated for use in subunit 
vaccines [Lee et al., 2017; Raghunandan et al., 2014]. RSV GCRR houses CX3C chemokine 
motif, which binds to host lymphocyte and monocyte CX3CR1, resulting in downregulation of 
host innate immune response [Polack et al., 2005]. Mab 131-2G, directed against a conserved 13 
amino acid region upstream to the CX3C motif, interferes with CX3C-CX3CR1 interaction, 
reducing innate immune modulation [Choi et al., 2012]. Palivizumab-binding antigenic site II, 
located on the surface of RSVF protein, is of interest because passively administered 
palivizumab antibodies have shown success in preventing RSV-associated disease in children 
[Scott, and Lamb, 1999]. However, recombinant RSVF or antigenic site II fragment production 
must achieve a helix-turn-helix conformation for host antibody recognition. To improve epitope-
binding affinity of antibodies, the use of computational design, modeling, and protein scaffolding 
has been used successfully to deliver RSVF antigenic site II fragments [Correia et al., 2014a].  
Therefore, we aimed to address several challenges associated with flagellin-based fusion 
and RSV vaccine development, and provide a rational basis for investigation and scalable 
production. Salmonella enterica ser. Typhimurium flagellin monomer FliC was modified to 
incorporate restriction enzymes in the hypervariable and terminal regions, allowing rapid in 
silico modeling, cloning, and characterization. With this expanded flagellin platform, we aimed 
to demonstrate (i) systematic modeling and cloning result in a design process capable of 
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selecting antigenic vaccine candidates; (ii) expression is scalable and robust, and provides a basis 
for standardized production, and (iii) D3 hypervariable region is compatible with structural 
modeling methodologies and use as a scaffold to achieve target epitope conformation.  
 
4.1.2 RSV fragment properties 
4.1.2.1 RSVG 
 
Respiratory Syncytial Virus Glycoprotein (RSVG), a glycosylated 289-residue 
attachment protein, allows RSV virus attachment to non-infected cells. Conserved cysteine rich 
region (GCRR, aa 164 – 176), located upstream of a CX3C chemokine motif (stabilized by 
cysteine noose) binds to host lymphocyte and monocyte CX3CR1 and has been shown to 
downregulate innate immune response [Polack et al., 2005] and is associated with increased 
cytotoxic T-cell immune activity [Boyoglu-Barnum et al., 2015]. 131-2G Mab directed against a 
5 residues (HVEVF) [Kauvar et al., 2010] within a conserved region upstream of the CX3C 
motif in the GCRR prevent CX3C-CX3CR1 interaction, reducing enhanced inflammation and 
pulmonary eosinophilia upon subsequent challenge with RSV A2 [Choi et al., 2012]. A non-
glycosylated region (residues 130 – 230) has been shown to increase antibodies to RSV in mice 
[Kim, and Chang, 2012]. VaxInnate evaluated two E. coli-produced FljB-RSVG constructs in 
vivo: STF2Δ.RSVG130-230 and STF2Δ.RSVG66-298, with the Δ representing some portion of 
the D2 or D3 region removed resulting in consistent antibody response for G130-230 and varied 
response for G66-298 [Song et al., 2015b]. 
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Fig. 14. RSVG protein and Central Conserved domain structure and schematic 
  
 	
37 
37	
The RSV A2 strain G protein is 298 amino acids long and consists of two heavily glycosylated mucin-like 
regions, separated by a central conserved, unglycosylated cysteine noose (yellow-green loop at the top) 
that is stabilized by a pair of disulfide bonds. The unglycosylated N terminus includes the cytoplasmic 
and transmembrane domains (blue). The glycans in this representation have slightly higher-than-
biological mass to reflect the probable space they would occupy. (Source: Structure and function of 
Respiratory Syncytial Virus glycoproteins [McLellan et al., 2013b]) 
 
4.1.2.2 RSVF 
Respiratory Syncytial Virus Fusion protein (RSVF) is a conserved 574-residue 
glycoprotein which fuses to host cell surface membranes and is a major target for RSV vaccine 
development [McLellan et al., 2013c]. Functional RSVF is a three-glycoprotein subunit trimer 
(F1, F2, F3) present in two major conformations: metastable pre-fusion and non-reversible highly 
stable post-fusion conformation, with pre-fusion eliciting stronger host neutralizing antibody 
response. Post-fusion RSVF x-ray crystal structures were resolved with binding antibodies, 
providing insight into RSVF neutralizing antibody structural and functional relationship and 
[McLellan et al., 2011]. Three major epitopes have been identified in RSVF: antigenic sites II 
(residues 254-277), IV (residues 422-438), and variable Ø (residues F1 196 -210, F2 62 – 69). 
RSVF antigenic site II is a helix-loop-helix conformation (Fig. 15 C), which Palivizumab 
(Synagis®) and Motavizumab bind specifically [McLellan et al., 2010]. Proper antigenic site II 
conformation is needed in recombinant protein design strategies, such as the computer-modeled 
scaffolding approach [Correia et al., 2014b]. RSVF antigenic site II and IV are accessible in pre 
and post-fusion conformations, but antigenic site Ø is only accessible in the prefusion 
conformation [McLellan et al., 2013a] (Fig. 15 A and B).  
A multivalent RSV construct administered separately with flagellin adjuvant did not 
show an increased antibody response in mice, [Subbarayan et al., 2010] but Recombinant RSVF 
attached to the N-terminal of FljB (produced in baculovirus) showed antibody titer from mice 
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sera [Song et al., 2015b].  
	
Fig. 15. RSVF and epitope structure 
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A) Prefusion and B) Postfusion structures of RSVF. Antigenic sites recognized by antibodies used in this 
study are indicated as follows: prefusion-specific site Ø (recognized by MAbs D25 and AM22), 
postfusion-specific site I (recognized by MAb 131-2a), site II (recognized by MAb palivizumab), and site 
IV (recognized by MAb 101F) [Widjaja et al., 2016]. C) RSVF antigenic site II modeled in I-TASSER 
and visualized in VMD to show helix loop helix conformation.  
 
Production of high-yield recombinant RSVF protein, a likely target for RSV vaccine design have 
been largely unsuccessful because of a failure to achieve proper prefusion RSV F conformation 
in high yield and is challenged by lack of purity and stability [McCarthy et al., 2014].    
 
4.1.3 Recombinant flagellin modifications/Synthetic FliC 
4.1.4 In silico prediction of fusion constructs 
Computational tools to predict recombinant protein and docking analyses have improved 
over the last 30 years and are routine in pharmaceutical industry drug design. Use of 
bioinformatic tools to characterize proteins may reduce trial and error approach by first 
eliminating constructs with lower likelihood of eliciting targeted response and second by 
prioritizing efforts in those constructs with high potential to be selected for cloning, and in vitro 
and in vivo evaluation.  
In silico prediction allows for rapid screening of multiple constructs for characteristics 
such as: solubility, secondary and tertiary structure, epitope conformation, mRNA translation 
efficiency, protein-protein interactions, and surface charge distribution. Immunogenic 
characteristics such as whole protein antigenicity and potential allergenic effects can be screened 
for potential host reactivity. 
3D modeling of recombinant proteins has application in vaccine research, allowing for 
screening of properties such as: epitope conformation and exposure, solubility, and active site 
conformation. 3D structure prediction modeling of proteins lacking crystal structures has gained 
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reliability and accuracy with Iterative Threading ASSEmbly Refinement method (I-TASSER) – a 
free for the academic community protein homology program [Yang, and Zhang, 2015] and 
ranked best among automated protein structure prediction programs [Cozzetto et al., 2009]. This 
composite method compares amino acid sequences to multiple-sourced Protein Database (PDB) 
files resolved experimentally by x-ray crystallography, NMR spectroscopy, or cryo-electron 
microscopy, and uses ab initio algorithms for unrecognized amino acid sequence regions, and 
atomic-level structure refinement [Roy et al., 2010]. I-TASSER identifies areas of subunit 
conflict, incorporating amino acid properties into the prediction model. For amino acid regions 
unrecognized by PDB homology, ab initio algorithm is used to predict most probable amino acid 
sequence conformation [Ab initio modeling of small proteins by iterative TASSERsimulations, 
2007]. Although experimentally determined 3D structures are superior to determining structure 
by homology modeling, predictive modeling can resolve structures for rapidly characterizing 
active sites and ligand docking analyses. Model accuracy is dependent upon available close 
homologous structures, allowing resolution as high as 1-2 Å, which may be appropriate for 
ligand-docking simulations, or 2-5 Å resolution for distantly homologous proteins [Roy et al., 
2010], which can predict active site function. Well-defined regions of fusion proteins, such as 
FliC in FliC-antigen constructs, may have strong homology to resolved structures in conserved 
regions, but vary in antigen-insert regions. Ramachandran plots are used to verify validity of 
PDB structure and assesses any conflicts between amino acids suggesting a strained region or 
model limitations.  
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Fig. 16. Protein homology modeling pipeline 
 
Molecular Dynamic Simulations, based on I-TASSER modeling, can be used to assess 
protein-ligand interactions. 3D model of TLR5 has been characterized and active sites 
determined by mutation analysis and truncation, allowing for in silico characterization of TLR5-
FliC interactions [Savar, and Bouzari, 2014]. Truncated recombinant FliC-antigen protein 
models developed in I-TASSER were evaluated by Molecular Dynamic Simulation using TLR5 
3D models and suggested some truncated and tagged versions may be less potent in TLR5 
activation than native conformations [Savar et al., 2013], but experimental in vitro or in vivo 
confirmation has not followed. Docking simulation technique has been applied to high-
throughput pipeline for evaluation [Binkowski et al., 2014] and may be useful in screening for 
steric hindrances of truncated and recombinant versions of FliC-antigens. 
In silico characterization of protein physiochemical attributes from primary amino acid 
structure may help inform strategies for purification and predict in vitro and in vivo measures 
related to potency. Rational vaccine design should consider stability and bioavailability of final 
product. Measures such as theoretical isoelectric point (pI), instability index, aliphatic index, and 
grand average hydropathy (GRAVY), are measured through ExPASy Prot Param server [Wilkins 
 	
42 
42	
et al., 1999]. In vivo assessment using recombinant influenza HA1-2-FljB (HA1-2 has a pI of 
9.0), revealed less immunogenicity, prompting the interpretation that high pI regions interacted 
with lower pI FljB at neutral pH to nullify effects [Song et al., 2014]. An instability index under 
40 suggests protein will be easy to work with and in vitro stability in test tube conditions at room 
temperature [Guruprasad et al., 1990]. A lower GRAVY score indicates decreased 
hydrophobicity and predicts greater protein stability as the concentration of PEG increases and 
inversely, a more positive score suggests greater protein instability as PEG concentration 
increases [Kraft, and Shell, 2007]. 
Predicting solubility of recombinant protein overexpression in E. coli would be useful in 
developing a purification strategy for a specific protein. Several bioinformatics tools are used to 
predict solubility character when overexpressed in E. coli. SOLPro, a free online bioinformatics 
tool, allows sequence-based evaluation of submitted residue sequence, providing a probability of 
solubility upon overexpression in E. coli [Magnan et al., 2009].         
 
4.1.5 Recombinant vaccine delivery platforms 
 
Despite successes of vaccination campaigns to lessen and eradicate global disease burden, 
traditional strategies such as live attenuated and inactivated vaccination remain limited. 
Production of traditional vaccines requires large volumes of materials, requiring lengthy 
production time. Safety of live- and attenuated-vaccines are a concern for production 
manufacturers as handling infectious materials pose a risk and live attenuated vaccines run the 
risk of reverting to virulent strains such as seen in simian immunodeficiency virus [Whatmore et 
al., 1995] and poliovirus [Pons-Salort et al., 2016]. Live-attenuated vaccines may lead to severe 
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reactions in immunocompromised individuals such as those living with AIDS [Löbermann et al., 
2012]. In addition, live attenuated vaccines present logistical challenges to distribution in 
countries lacking adequate infrastructure and refrigeration and require cold-chain delivery 
[Volkin et al., 1996].  
Recombinant subunit vaccines have the potential to address shortcomings of live- 
attenuated and inactivated whole-cell vaccines because they are largely composed of antigens 
and adjuvants important for targeted immune response and lack extraneous cell components, 
minimizing risk of adverse reactions in the host [Nascimento, and Leite, 2012]. Recombinant 
vaccines may also be used in conjunction with other recent biotechnology advances such as 
nanoparticles to deliver dose and particle cocktails to modulate host immune response [Ulery et 
al., 2011]. Inactivated virus vaccines, although safer, may lose immunogenicity during 
inactivation due to conformational changes of antigenic epitopes [Fan et al., 2015].    
Recombinant subunit vaccines, although safer, may be limited in their ability to evoke 
long-lasting immunity in the host. Adjuvant activity, which is inherently present in live 
attenuated vaccines, may be needed for long-lasting protection against certain pathogens [Pérez 
et al., 2012]. Recombinant subunit vaccines do not stimulate a robust mucosal or cytotoxic T-cell 
response, which is important for clearing intracellular pathogens [Nascimento, and Leite, 2012]. 
Adjuvant components may need to be included in some recombinant vaccine solutions to 
facilitate immune system recognition and stimulation [Brito, and O’Hagan, 2014].  
Vaccine platforms, a generic modular system to facilitate design and manufacturing of 
similar vaccine products with immune-stimulating component(s), can address shortcomings of 
recombinant subunit vaccines. Platform technology is ideal for standardizing development and 
production of related vaccine products, allowing for streamlined manufacturing and meeting 
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regulatory standards. Immunogenicity can also be enhanced in a targeted way through the 
platform as core immunogenic or modular components. For example, a woodchuck hepatitis core 
antigen (WHcAg) was evaluated as a vaccine platform, in combination as a Virus-like particle 
(VLP) for different types of antigen inserts [Billaud et al., 2005]. This technology sought to 
address some of the production and immunostimulatory challenges associated with standard 
hepatitis core antigen delivery system. 
A tailorable vaccine platform allows screening of multiple antigenic components to test 
formulations evoking an appropriate host immune response to the antigen. Some of the early trial 
and error approaches to flagellin systems included a few constructs arranging antigens in 
different locations of the flagellin, but a systematic screening strategy has not been documented. 
However, VaxInnate does incorporate rational design into their design and evaluation strategy 
[Song et al., 2010] and make inferences based on structure, behavior, and physiochemical 
properties, but it is not clear how formalized this approach is.       
 
4.1.6 Synthetic FliC Platform 
 
To facilitate rapid design, screening, cloning, and evaluation of flagellin-based fusion 
constructs, Salmonella enterica serovar Typhimurium LT2 flagellin monomer FliC (Genbank 
Acquisition D13689) was modified to remove terminal D0 regions and incorporate 22 common 
restriction enzyme sites (Synthetic FliC – 1287 bp). Fourteen sites were placed in the 
hypervariable D3 domain, maintaining native flagellin D3 length to ensure proper D1 TLR5-
binding configuration. Four and two sites were incorporated on the N and C- D1 terminal ends, 
respectively. The Synthetic FliC platform construct was optimized for expression in E. coli, 
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synthesized by DNA 2.0 (Menlo Park, CA) in expression vector pJ404 under the control of an 
inducible T5/Lac operon promoter, and modified by PCR to include a C-terminal 6x Histidine 
tag (Fig. 17). 
 
Synthetic FliC platform design   
Synthetic FliC (1287 bp, 45 kDa) (Fig. 17) was designed, 6x histidine tag added, and 
confirmed by DNA sequencing. Synthetic FliC construct was 100% homologous to native 
Salmonella Typhimurium LT2 flagellin amino acid sequence homology in D1 and D2 domains 
and 75% homologous in the synthetic D3 hypervariable, as determined by BLAST 
[NCBI Resource Coordinators, 2017].  
 
	
Fig. 17. Synthetic FliC platform schematic 
Modified Salmonella enterica serovar Typhimurium FliC (Synthetic FliC) schematic representation 
incorporating 14, 4, and 2 restriction enzyme sites in the D3 hypervariable, D1 N-terminal, and D1 C-
terminal, respectively. Construct was synthesized by DNA 2.0 (Menlo Park, CA).   
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 Materials and Methods 4.2
Construction, design, and screening of in silico Synthetic FliC-RSV library  
A Synthetic FliC-RSV fusion construct library was designed, modeled, screened, and 
visualized in I-Tasser® [Yang et al., 2015] homology modeling program and Visual Molecular 
Dynamics (VMD)® software. RSVG (A2 130 -230) was inserted and modeled in three Synthetic 
FliC locations: 1) by replacing ~60% of the hypervariable D3 region (SacI and AvrII - 
RSVGReplace), 2) by inserting between two consecutive restriction enzyme D3 sites (NdeI and 
MfeI - RSVGAdd), or added to the N-terminal domain (NcoI and SpeI - RSVGN). RSVGAdd 
incorporated 100 residues, removing only 7, thereby increasing the hypervariable region by 93 
residues, doubling the D3 region. RSVGReplace removed 70 Synthetic FliC residues and 
replaced 100, increasing D3 region by 30 residues. Characteristic three lateral α-helices TLR5-
binding conformation in D1 domain and blockage by insert was qualitatively assessed for all 
constructs. 
RSVF antigenic site II (aa 255 – 278) was evaluated in Synthetic FliC hypervariable D3 
domain for epitope exposure, stability, and helix-turn-helix conformation. To select insertion 
location in the hypervariable region, 10 D3 restriction site combinations, separated by 3 
restriction enzyme sites (~65 bp) were modeled and screened for general epitope exposure. At 
selected D3 site, two strategies were used to build a library of putative Synthetic FliC-RSVF 
antigenic site II constructs: 1) matrix residue method- 16 constructs generated by addition of 0, 
1, 2, and 3 native RSVF amino acids added to terminal ends of antigenic site II insert and 2) 
flanking native residue method- generating 3 constructs by extending epitope insert with 7, 9, 
and 11 native RSVF amino acid residues to mimic native torsional effects (Fig. 18). One 
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Synthetic FliC-RSV construct from each strategy (RSVGReplace, RSVGAdd, RSVGN, Pali1, 
and Pali2) was selected for cloning and in vitro evaluation (Fig. 19).  
	
Fig. 18. RSVF antigenic site II insert design methods 
A) Matrix residue method adds combinations of 0 – 3 native RSVF on N and C terminal ends. B) 
Flanking Native Residue method adds 7, 9, and 11 native RSVF residues to N and C terminal ends       
 
All FliC-RSV 3D structures were evaluated by Ramachandran plot in RAMPAGE 
[Lovell et al., 2003]. Favorable percent amino acid configuration was calculated for RSVG 
GCRR and RSVF antigenic site II antibody-binding regions.   
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Fig. 19. Schematic representation of selected FliC-RSVG and FliC-RSVF antigenic site II fusion 
constructs 
Schematic diagram of three Synthetic FliC-RSVG (residues 130 -230 – shown in red) constructs: cloned 
into NcoI and SpeI sites (RSVGN) and hypervariable region between NdeI and MfeI (RSVGAdd) and 
replacing 210 bp (70 residues) of hypervariable D3 between AvrII and SacI (RSVGReplace). Synthetic 
FliC-RSVF antigenic site II constructs: palivizumab-binding antigenic site II (residues 255 – 278 – shown 
in light green) cloned into SphI and BglII sites with nine native RSVF residues flanking (residues 246 – 
287 - shown in pink) to act as a flanking native “linker” piece between epitope insert and Synthetic FliC 
(Pali2) and two residues on the N-terminal end (PaliI).  
 
Primary structure and physicochemical characteristics.  
Physiochemical characteristics such as theoretical isoelectric point (pI), molecular 
weight, and instability index [Guruprasad et al., 1990] of FliC-RSV fusion constructs, were 
evaluated using ExPASy Prot Param server® [Wilkins et al., 1999].  
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Synthetic FliC-RSV fusion protein construction, expression, and purification 
Cloning 
RSV inserts were subcloned from RSVG or RSVF housed in pET22b® and pFastBac1® 
plasmids, respectively. PCR primers were designed with compatible restriction sites and cloned 
in frame into Synthetic FliC in pJ404. Recombinant Synthetic FliC-RSV pJ404 plasmids were 
transformed into electrocompetent E. coli BL21 (New England Biolabs, C2530) and verified by 
colony PCR, restriction digest mapping, and DNA sequencing.  
 
Growth and Expression 
Flask. Synthetic FliC-RSV series was grown to OD600 ~ 4 in 1 L TB shaking at 250 RPM 
at 37°C, supplemented with carbenicillin (100 mg/L), and induced with 2 mM IPTG for 3.5 h. 
Cell pellets were collected by centrifuging at 5,000 RPM for 10 min at 4°C. Culture samples 
were sonicated and evaluated on SDS-PAGE electrophoresis, stained by Coomassie brilliant 
blue, and analyzed by ImageJ® for percent total protein.    
 
Fermentation  
RSVGReplace was adapted to ECAM with 100 µg/mL carbenicillin, and 30 mL starter 
culture used to inoculate Biostat 30 C+ Bioreactor at 12 L total volume using 10 L batch medium 
with 100 µg/mL ampicillin at 37oC. When glucose was exhausted (OD600 = 30), feed medium 
with 100 µg/mL carbenicillin was added and induced with 1 mM IPTG for 3.5 h when OD600 
reached 55. Harvests were collected by Carr PowerFuge and packed wet weight determined.  
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Purification  
FliC-RSVF-induced E. coli cell paste was disrupted in 1g/5mL Lysis Buffer (50 mM 
Tris-base, 125 mM NaCl, 4% sucrose, 0.05% TritonX-100, pH 8), lysed by sonication on ice 3x 
using 4 second pulses for 20 seconds in presence of Roche® mini cOmplete protease inhibitor 
cocktail, incubated at 30oC for 1 h, and centrifuged at 10,000 RPM at 23oC for 10 min. PEG 
3350 was added to supernatant to 14% (w/v), stirred at room temperature, and centrifuged at 
10,000 RPM for 60 min at 15oC. Pellet was resuspended in Resuspension Buffer (20 mM Tris, 
100 mM sucrose) and centrifuged at 10,000 RPM for 60 min at 15oC. The supernatant was 
treated with 1% (v/v) TritonX-114, stirred for 15 min and 5% (w/v) PEG 3350 added and stirred 
for 15 min, followed by 3 h and 10,000 RPM centrifugation at 24°C. Aqueous layer was filtered 
by 22 µm syringe, dialyzed overnight to binding buffer (20 – 40 mM imidazole, 20 mM sodium 
phosphate, 0.5 M NaCl, pH 7.4) in Spectra/Por MWCO 3,500 dialysis membrane, applied to 1 
mL nickel column (GE HisTrap) at 1 mL/min, and eluted with 5 CV elution buffer (20 mM 
sodium phosphate, 300 mM imidazole, 0.5 M NaCl, pH 7.4) at 0%, 20%, 40%, 60%, 80%, and 
100% step gradient. FliC-RSVG-induced E. coli cell paste was treated using the same disruption 
and nickel column purification steps, but PEG precipitation and 2-phase separation were not 
used.     
 
Characterization of FliC RSV fusion constructs 
Purified Synthetic FliC-RSV fusion constructs were quantified by Bradford assay [32] 
and purity evaluated by SDS-PAGE and ImageJ®. FliC-RSVG was confirmed by Western blot 
using primary Mab 131-2G (Millipore MAB858-2) (1:2000) and secondary HRP anti-mouse 
(1:2000) antibodies. FliC-RSVF used primary Synagis® Palivizumab (1:750) and secondary HRP 
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anti-human (1:2000), followed by visualization on LAS4000 mini. Endotoxin levels were 
assessed by Charles River Kinetic Limulus Amebocyte Lysate Endosafe Endochrome assay 
(R1708K). 
 
ELISA 
Purified FliC-RSV constructs, positive control whole-cell FI-RSV, and negative control 
Synthetic FliC, were diluted 1:2 in carbonate-bicarbonate buffer (pH 9.6) over a range of 4 
µg/mL to 40 ng/mL (FliC-RSVG series) and 40 µg/mL to 0.5 µg/mL (FliC-RSVFPali series), 
respectively. Samples were incubated for 12 h at 4°C in a flat bottom 96-well plate (Costar 3590) 
and blocked with 5% dry non-fat milk in PBST at 37oC for 1 h. All washing steps were 
performed in PBST (pH 7.4) and blocked with 5% dry non-fat milk in PBST at 37oC for 1 h. 
Samples were incubated with primary Mab 131-2G (1:2000) and Synagis® Palivizumab (1:750) 
at 37°C for 1.5 h, washed, and incubated with secondary anti-mouse IgG antibody (1:2000) for 
FliC-RSVG constructs and secondary anti-human IgG antibody (1:2000) for FliC-RSVFPali. 
Samples were incubated with 100 µl/well 1x 3,3’,5,5’-tetramethyl benzidine (TMB) Substrate 
Solution (eBioscience) for 3 minutes at room temperature and stopped with 100 µl/well 1M 
H3PO4. Absorbance was measured at 450 nm on Wallac® Victor 1420 Multilabel Counter. 
 
TLR5 assay  
HEK-Blue cell line expressing mTLR5 (Invivogen, San Diego, CA) was cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, D5546), supplemented with 10% fetal 
bovine serum (Gibco) and 1x antibiotics (50 U/ml penicillin, 50 µg/mL streptomycin, 100 µg/mL 
Normacin, 2 mM L-glutamine and Zeocin (100 µg/mL) and Blasticidin (30 µg/mL)). After 
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resuspending 1.4 x 105 cells in HEK-Blue Detection media (Life Technologies), FliC-RSV series 
and whole FljB was added in 1:10 serial dilutions from 100 µg/mL to 1 pg/mL. After 24 h 5% 
CO2 incubation at 37°C, the TLR5 activity of fusion constructs were evaluated by measuring the 
activity of secreted embryonic alkaline phosphatase (SEAP) detected at OD630 on Wallac plate 
reader.   
 
 Results 4.3
4.3.1 In silico screening and characterization 
4.3.1.1 Primary structure and physiochemical characteristics 	
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Theoretical molecular weights of selected constructs were predicted and character 
summarized (Table 9).  FliC-RSVG constructs had theoretical isoelectric points (pI) greater than 
Synthetic FliC or FliC-RSVF constructs, due to a positively charged RSVG insert region (aa 130 
-230) with a pI of 10.4. All models predicted instability indices below 40, suggesting in vitro 
stability. Propensity for solubility upon overexpression was predicted to be 60 - 70% for 
Synthetic FliC and Synthetic FliC-RSVF antigenic site II fusion constructs and 80 - 90% for 
Synthetic FliC RSVG constructs (Table 10).   		
Table 9. Description of FliC-RSV series 	 		
 
 
 
 			
Table 10. Synthetic FliC-RSV series physiochemical properties 
 
Name	 Description	 MW	
(kDa)	
RSVGAdd	 RSVG	added	to	D3	hypervariable		 55	
RSVGReplace	 RSVG	replaces	2/3	of	hypervariable	 50	
RSVGN	 RSVG	added	to	N-terminal	 55	
Pali1	 RSVF	antigenic	site	II	flanked	by	2	aa	on	N-terminal	 44	
Pali2	 RSVF	antigenic	site	II	flanked	by	9	aa	on	N	and	C-terminal	 44	
Sequence 
Variant 
Native 
FliC6x 
Synthetic 
FliC 
RSVGAdd RSVGN RSVGRep RSVFPaliI RSVFPaliII 
MW (kDa) 52.8 45.2 55.9 56.0 49.0 46.2 49.5 
pI 5.07 5.88 9.32 9.16 9.34 5.67 5.23 
Instability 
Index 
24.51 23.92 23.91 22.78 21.05 24.51 23.70 
SolPro 
prediction 
of solubility 
0.65 0.68 0.88 0.81 0.85 0.65 0.62 
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4.3.2 FliC-RSV in silico tertiary structure screening and characterization 
All Synthetic FliC-RSVG models displayed characteristic three lateral α-helix structure 
required for TLR5-binding and lacked noticeable interference from insert sequence (Fig. 20- F, 
G, and H). GCRR Mab 131-2G-binding epitope was fully exposed in RSVGN and partially 
exposed when placed in the hypervariable region in RSVGAdd and RSVGReplace constructs 
(Fig. 20-F and G).     
 Placement of RSVF antigenic site II in Synthetic FliC hypervariable region was selected 
by evaluating restriction enzyme site combinations spaced by approximately 30 bp apart. SphI 
and BglII restriction enzyme sites were selected among 10 combinations by modeling inserted 
antigen in I-TASSER and qualitatively assessed for epitope exposure. Among the 16 FliC-RSVF 
antigenic site II constructs generated by the matrix method, matrix cell 2,0 (2 native RSVF 
amino acids on N-terminus of insert) displayed the greatest epitope surface exposure (Fig. 20 B 
and C). Among the three generated FliC-RSV constructs using the flanking residue method, the 
construct with nine native RSVF residues added to each end (Fig. 20 D and E) was predicted to 
have optimal epitope presentation and support for helix-loop-helix conformation.  
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Fig. 20. 3D representation of selected Synthetic FliC-RSVG and FliC-RSVF Pali constructs. 
Models generated in I-TASSER and VMD. TLR5-binding D1 domain - orange, D2 - pink, Synthetic MCS 
hypervariable (D3) domain – blue, RSVG or RSVF non-epitope insert – red. Antibody binding epitopes: 
GCRR Mab 131-2G - yellow, inserts, and RSVF antigenic site II – light green. A) Synthetic FliC, B) 
RSVFPaliI D3 domain C) RSVFPaliI D3 domain at 90° D) RSVFPaliII D3 domain E) RSVFPaliII in D3 
domain at 90° F) RSVGReplace RSVG insert in hypervariable region, G) RSVGAdd RSVG insert in 
hypervariable region, H) RSVGN showing RSVG attached to N terminus D1 region.  
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Table 11. FliC-RSV fusion construct 3D model epitope exposure and conformation evaluation in 
VMD  
Construct Epitope exposure 
G Series  
RSVGN Fully 
RSVGAdd Partially 
RSVGRep Partially 
F Series  
Pali1 Fully 
Pali2 Fully 
 
 
4.3.3 Expression, purification, and analyses of Synthetic FliC-RSV constructs 
Flask cultures (1L) induced with 2 mM IPTG yielded 2 g cell paste per liter after 3.5 h 
with recombinant FliC-RSV protein representing ~ 20% total cell protein (Fig. 21), and 12L 
bioreactor produced 850 g packed cell wet weight of E. coli expressing RSVGReplace construct. 
Synthetic FliC RSVG series was purified to ~70% and Synthetic FliC-RSVF PaliI and Pali2 
purified to  >95% (Fig. 22A). Antigen presence was confirmed by Western blot, with strongest 
Mab 131-2B and palivizumab antibody reactivity with RSVGN and Pali2, respectively (Fig. 22 
B and C). Final endotoxin concentration for Pali1 and Pali2 were < 0.05 EU/µg of protein. 
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Fig. 21. Synthetic FliC-RSV series flask induction  
Synthetic FliC-RSV constructs were induced with 2 mM IPTG (+) and compared to non-induced cultures 
(-). Total lysate samples were loaded on 4-12% Bis-Tris SDS-PAGE at 5µg/lane and stained by 
Coomassie. 
 
 
 
 
 
 
 
 
 
 
 
L	 L	 L	
Pali1	 Pali2	 RSVGAdd	 RSVGN	 RSVGRep	 Syn	FliC	
(-)	 (-)	(-)	(-)	(-)	(-)	(+)	 (+)	 (+)	 (+)	 (+)	(+)	kDa	
65	
50	
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Fig. 22. Soluble FliC-RSV fusion protein characterization 
Synthetic FliC-RSV fusion constructs were expressed, purified, and evaluated on SDS-PAGE A) 2 µg 
purified fusion construct per lane stained with Coomassie blue and transferred to nitrocellulose 
membranes for Western blot. B) FliC-RSVF Pali series probed with Synagis® (Palivizumab) (1:750) and 
C) Synthetic FliC-RSVG series probed with Mab 131-2G (1:2000) antibody.  
 
4.3.4 Comparative Synthetic FliC-RSV construct antibody affinity 	
Relative antigenicity of purified Synthetic FliC-RSV constructs was assessed using 
indirect ELISA. The strongest reactivity among the Synthetic FliC-RSVG series was seen in 
RSVGN (Fig. 23 A) and Pali2 among Synthetic FliC-RSVFPali constructs (Fig. 23 B). All 
Synthetic FliC-RSV fusion constructs showed stronger antibody affinity than FI-RSV control.   
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Fig. 23. ELISA of FliC-RSVG and RSVF Pali series. 
Binding of anti-GCCR (Mab 131-2G) to purified RSVG fusion series (A) and Palivizumab to FliC-
RSVFPaliI and (B) Pali2 was assessed by indirect ELISA.  			
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4.3.5 Comparative TLR5 activity of FliC-RSV constructs 	
The ability of FliC-RSVFPali2, RSVGN, and RSVGReplace to TLR5 activity was 
evaluated by the in vitro HEK293 TLR5 assay. All tested FliC-RSV constructs induced TLR5 
activity, but with EC50s of ~800 times greater than FljB, representing decreased comparative 
bioactivity (Fig. 24).  
 
	
Fig. 24. Synthetic FliC-RSV fusion construct activation of mTLR5 
HEK293 cell lines expressing TLR5 were exposed to indicated amounts of Synthetic FliC-RSV or whole 
FljB flagellin for 24h. TLR5 stimulation was determined by measuring secreted embryonic alkaline 
phosphatase (SEAP) activity and analyzed at OD630.  
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 Discussion 4.4
We have attempted to increase the flexibility and applicability of flagellin as a vaccine 
platform by incorporating 22 restriction enzyme sites in the hypervariable D3 and terminal ends. 
An expanded flagellin platform, capable of housing antigen inserts in different regions and 
conformation, would enhance screening, evaluation, production, and rational design of fusion 
constructs to improve strategies to target challenging immunogenic responses of pathogens and 
provide an alternative to large-scale production of difficult to produce proteins.  
Among the 22 Synthetic FliC-RSV fusion constructs (3 FliC-RSVG and 19 FliC-RSVF) 
screened in silico, the five tested in vitro all showed antibody-binding affinity. We find that 
Pali2, consisting of Synthetic FliC expressed with the RSVF antigenic site II epitope in the D3 
hypervariable region and RSVGN, comprised of Synthetic FliC attached with RSVG on the N-
terminal end, demonstrate highest specific antibody-binding activity.  
 Flagellin-based fusion constructs are being evaluated as vaccine candidates, but 
construct design has centered on the expression of the whole protein or large amino acid 
segments added to hypervariable and terminal D0 regions. Previously, large protein segments 
were incorporated into or replaced the hypervariable region with linker pieces used to offset 
steric interference [Song et al., 2009], requiring additional design modification and in vitro 
screening. In this project, we demonstrated the screening and integration of small-targeted 
epitopes in the hypervariable region while retaining epitope and D1 TLR5-binding presentation 
and conformation. Smaller inserts (33 and 51 residues), such as the RSVF antigenic site II 
epitope insert used in the FliC-RSVF constructs were easily modeled, cloned, and expressed in 
the Synthetic FliC platform system. A strategy incorporating small inserts for fusion constructs 
may be useful in developing standardized production processes because large inserts introduce 
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additional biophysical property variation, may require codon optimization, and may introduce 
unintended proteolytic cleavage sites to the product, requiring additional characterization and 
screening.  
Typical strategies to produce immunogenic RSVF constructs involve the production of 
full-length protein to ensure proper native epitope conformation and exposure. Alternatively, we 
demonstrated the use of scaffolding in the hypervariable region of Synthetic FliC using 
computational modeling and predicted areas with the highest likelihood of proper epitope 
presentation, orientation, and exposure (Fig. 20 B, C, D, E), resulting in selection two FliC-
RSVF antigenic site II constructs with palivizumab antibody-binding affinity as confirmed by 
ELISA (Fig. 23) and Western blot (Fig. 22, B, C). Use of prediction models for RSVF antigenic 
site II epitope identified a location capable of supporting exposure and selecting constructs most 
likely to result in antigenicity. Pali2, designed by incorporating 9 residue linker pieces flanking 
the RSVF antigenic site II, resulted in the FliC-RSVFPali construct with highest antibody 
affinity.  
RSVGN showed the strongest antibody affinity among the FliC-RSVG series. 
Assessment of 3D models predicted GCCR Mab 131-2G antibody-binding region to be partially 
buried when placed in the hypervariable region (Fig. 20 F and G). Also, RSVG 130 – 230 aa 
insert has a theoretical pI of 10.4, resulting in a pI >9.1 for FliC-RSVG proteins (Table 10), 
which has previously shown to be problematic for aggregation at neutral pH and likely the cause 
of poor immunogenicity when injected into animals [Song et al., 2009]. Future studies may 
remove regions upstream of the CX3C antibody-binding region that contributes to the high pI of 
RSVG (130 -230 aa) and is unnecessary for antibody binding.  
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Standardized overexpression was achieved in small flasks at ~20% total protein (Fig. 21), 
suggesting the varied antigen insert and placement did not alter expression and was overall 
robust. Pilot-scale bioreactor production of RSVGReplace yielded 850g packed wet weight cell 
paste, suggesting scalable production. ELISA and Western blot results showed decreased 
antibody affinity and possible degradation (Fig. 22A and 22B, respectively), which may be the 
result of cell paste handling.  
TLR5 activity of Synthetic FliC-RSV fusion series was lower than native FljB by 750 – 
900 fold (Fig. 24), suggesting reduced bioactivity of recombinant fusion constructs. These results 
are consistent with previous reports suggesting that D0 regions may facilitate and stabilize 
flagellin-TLR5 interaction [Song et al., 2009; Eaves-Pyles et al., 2001; Lu, and Swartz, 2016]. 
However, modulation of TLR5 affinity by D0 domain removal may be beneficial for targeting 
diseases such as RSV that may promote enhanced reactogenicity or vaccine-enhanced disease. 
Also, adaptive immunity may be strengthened by flagellin monomers lacking NLRC4-
stimulating D0 domain [Li et al., 2016], and there is therefore a need to explore modified 
iterations of TLR5 stimulatory molecules to elicit varied host response.  
  The ability to screen multiple constructs early in the fusion protein design process will 
improve the selection of putative candidates by minimizing in vitro evaluation, and standardize 
expression and purification. Structure and homology prediction from 3D modeling has been 
performed with recombinant FliC for TLR5 activity [Savar et al., 2014b], and additional 
computational tools would be compatible to use with this synthetic platform to model antibody 
or TLR5-binding strength, charge distribution, and predict compatibility with expression, 
production, and purification strategies. Our selection of flagellin-based fusion proteins was 
influenced by our experience showing pre-pilot scale over-expression with a reliable and scalable 
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purification process, yielding a product that meets FDA endotoxin standards. Based on this 
manufacturing process, recombinant subunit production is inexpensive, and use of platform 
fermentation technology with E. coli is robust, well characterized, and reliably consistent.  
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